ALKAMI TECHNOLOGY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ALKAMI TECHNOLOGY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $152.16M | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | $112.14M | Feb 25, 2022 |
| FY2021 | Dec 31, 2019 | $73.54M | Feb 25, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $443.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $333.85M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $264.83M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $204.27M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $152.16M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $112.14M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $73.54M | Feb 25, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $196.63M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $144.11M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $108.32M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $83.81M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $59.16M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $30.44M | Feb 25, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($47.65M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($40.84M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($62.91M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($58.60M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($46.82M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($51.36M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($41.87M) | Feb 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($53.64M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($44.63M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($63.71M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($57.69M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($42.92M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($35.10M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($42.54M) | Feb 25, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $96.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $84.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $69.33M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $48.80M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $40.21M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $32.72M | Feb 25, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($17.50M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($38.05M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($28.96M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($38.15M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($39.09M) | Feb 25, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.06M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.06M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.12M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.15M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $3.69M | Feb 25, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $847.23M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $437.28M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $399.83M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $488.89M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $436.51M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $249.17M | Feb 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $485.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $80.25M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $74.88M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $154.84M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $91.90M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $69.43M | Feb 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $362.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $357.03M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $324.94M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $334.05M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $344.61M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | ($263.52M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | ($195.39M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | ($153.86M) | Feb 25, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $403.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $148.05M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $148.05M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $148.02M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $48.09M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $16.22M | Feb 25, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($523.85M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($476.20M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($435.37M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($372.45M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($313.85M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($263.53M) | Feb 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $94.36M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $40.93M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $108.72M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $308.58M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $166.79M | Feb 25, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $84.58M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $24.62M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $24.88M | Feb 25, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (11) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | (9) | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (11) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | (9) | Feb 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 106.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 102.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 96.72M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 92.11M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 89.95M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 4.91M | Feb 25, 2022 |